Effect of 90-yttrium-Ibritumomab Tiuxetan in patients with Non-Hodgkin Lymphoma

Trial Profile

Effect of 90-yttrium-Ibritumomab Tiuxetan in patients with Non-Hodgkin Lymphoma

Completed
Phase of Trial: Phase IV

Latest Information Update: 13 May 2015

At a glance

  • Drugs Ibritumomab tiuxetan (Primary) ; Rituximab
  • Indications Diffuse large B cell lymphoma; Follicular lymphoma; Marginal-zone-B-cell-lymphoma; Non-Hodgkin's lymphoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 13 May 2015 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top